ETX 101
Alternative Names: AAV-ETX; Dravet syndrome viral gene therapy - Encoded Therapeutics; ETX101Latest Information Update: 24 Feb 2025
At a glance
- Originator Encoded Therapeutics
- Class Antiepileptic drugs; Gene therapies
- Mechanism of Action Gene transference; SCN1A protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Dravet syndrome
Most Recent Events
- 13 Feb 2025 ETX 101 receives Fast Track designation for Dravet syndrome [Intraventricular,Infusion] (In children, In infants, Treatment-experienced) in USA
- 07 May 2024 Pharmacodynamic data from a preclinical studies released by Encoded Therapeutics
- 30 Apr 2024 Phase-I/II clinical trials in Dravet syndrome (In children, In infants, Treatment-experienced) in USA (Intraventricular) (NCT05419492)